Deal Details
Convertible Senior Notes
Summary
Baird served as a co-manager on this offering.
About
TESARO, Inc. (“TESARO” or the “Company”) (NASDAQ-GS: TSRO) recently priced an offering of $201 million aggregate principal amount of 3.00% Convertible Senior Notes due 2021. The Company intends to use the net proceeds from the offering to fund commercialization activities for rolapitant (oral formulation), clinical trials for rolapitant (intravenous formulation), niraparib and TESARO's other product candidates, to carry out TESARO's immuno-oncology platform strategy and for working capital and general corporate purposes.TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. TESARO has in-licensed and is currently developing three product candidates, rolapitant (filed NDA for oral formulation and in Phase 3 for intravenous formulation), niraparib (Phase 3) and TSR-011 (Phase 1/2a), and in March 2014 the Company initiated its immuno-oncology platform strategy by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc. for the discovery and development of antibodies for immuno-oncology targets. TESARO is headquartered in Waltham, Massachusetts.
For additional information about this transaction, please contact:
- Date
- October 2014
- Company
- TESARO, Inc.
- Transaction
- M&A
- Sectors
- Healthcare
- Target Geography
- North America
Share
